China NMPA Medical Device Registration
Access the world's second-largest medical device market — USD 100B+ China. NexorTest delivers complete NMPA registration across Class I–III, Chinese agent services, updated 2025 regulatory compliance, new GMP 2026 readiness, and specialized SaMD and IVD registration pathways.
China — NMPA Medical Device Market
1.4B+ Population | USD 100B+ Medical Device Market | 2025 Revised Regulations | New GMP Nov 2026 | Priority Review for AI/High-End Devices
NMPA Medical Device Classification System
China uses a three-class risk system. The January 2026 catalogue update adjusted classifications for 31 device categories — verify your device class before registration
Notification (Filing)
Simple, low-risk devices. Filing process with local district FDA authority. No formal review required. Basic technical documentation. New 2025 scope: excludes sterile devices (now min Class II).
- Non-Sterile Bandages
- Exam Gloves
- Basic Diagnostics
Registration — Provincial
Moderate-risk devices reviewed by provincial FDA. Home country approval required. Chinese GMP inspection may apply. Sterile devices, powered surgical instruments, IVD reagents. Jan 2026 catalogue adjustments apply.
- Powered Instruments
- IVD Reagents
- Sterile Devices
Registration — National NMPA
Highest-risk devices reviewed by NMPA centrally. 2025 expanded scope includes implanted devices, drug-device combinations, standalone high-risk SaMD, absorbable materials, and all AIMD. Priority review available for innovative devices (Announcement 63/2025).
- Pacemakers
- Coronary Stents
- High-Risk SaMD
- Drug-Device Combo
NMPA 2025–2026 Key Updates
China's NMPA has issued major regulatory changes — understanding these is critical to your registration strategy
January 7, 2025
Revised Administration Regulations
New Medical Devices Supervision and Administration Regulations clarify registrant/filer responsibility for full lifecycle quality management. Optimized registration review process with defined deadlines for NMPA responses. Enhanced post-market surveillance obligations.
July 9, 2025
Priority Review — High-End Devices
Announcement 63/2025: NMPA establishes expedited review for innovative high-end medical devices. Priority areas: medical robots, advanced imaging systems, AI-driven diagnostic/therapeutic technologies, novel biomaterial devices, and next-generation implantables.
November 4, 2025
New GMP Standards — Effective Nov 2026
New Good Manufacturing Practice for Medical Devices issued, replacing 2014 GMP. Effective November 1, 2026. Key changes: more stringent QMS requirements, enhanced personnel qualifications, strengthened supply chain control, and improved documentation standards. All China-registered manufacturers must comply.
January 4, 2026
Classification Catalogue Update
Announcement adjusting Medical Device Classification Catalogue for 31 device categories, effective immediately. Manufacturers with affected products must verify current classification and may need to adjust registration pathway. NexorTest provides classification verification as a standalone service.
Complete NMPA Registration Services
From device classification to post-market compliance — NexorTest navigates China's complex regulatory landscape on your behalf
📋
NMPA Registration (Class I–III)
Complete NMPA registration management across all three device classes. Chinese-language technical dossier, Chinese agent coordination, provincial and national FDA submission, query response, and certificate management.
- Class I–III
- Chinese Dossier
- Full Management
🇨🇳
Chinese Registration Agent (CRA)
NexorTest partners with established Chinese entities to provide mandatory CRA services. Your Chinese agent manages all NMPA regulatory obligations, adverse event reporting, and post-market surveillance compliance.
- CRA Services
- Legal Entity
- NMPA Liaison
🤖
SaMD & AI Device Registration
Specialized NMPA registration for Software as a Medical Device and AI-driven medical devices. Class III SaMD strategy, algorithm validation data, clinical performance compilation, cybersecurity assessment, and IEC 62304 documentation.
- SaMD Class III
- AI/ML Devices
- IEC 62304
🔬
IVD Registration China
Expert NMPA registration for In Vitro Diagnostic devices. IVD classification, analytical and clinical performance data, reagent dossier preparation, and post-market IVD vigilance setup for the Chinese IVD market.
- IVD Class I–III
- Performance Data
- Reagents
🏭
New NMPA GMP 2026 Compliance
Pre-compliance gap analysis against new NMPA GMP standards effective November 2026. QMS upgrade roadmap, documentation enhancement, supply chain control improvements, and personnel qualification planning. Deadline: November 1, 2026.
- GMP Nov 2026
- Gap Analysis
- QMS Upgrade
⚡
Priority Review Strategy
Leverage NMPA's Announcement 63/2025 priority review pathway for innovative devices. Eligibility assessment for medical robots, advanced imaging, AI diagnostics, and novel biomaterials. Strategic positioning for expedited NMPA approval.
- Priority Review
- AI Devices
- Medical Robots
NMPA Registration Step-by-Step
Classification & Strategy
Device classification per 2025/2026 NMPA catalogue, priority review eligibility assessment (Announcement 63), home country approval leverage analysis, and registration pathway planning.
Chinese Agent Appointment
NexorTest coordinates Chinese Registration Agent (CRA) appointment. NMPA account registration, import authorization, and legal entity documentation for foreign manufacturer representation in China.
Chinese Technical Dossier
Complete Chinese-language technical dossier including device description, performance testing, clinical data, GMP certificates, risk management, and home country approval certificates.
NMPA/Provincial Submission
Class II: submission to provincial FDA authority. Class III: national NMPA submission. Technical review management, query response, and expert panel coordination where required.
GMP Inspection Readiness
Pre-GMP inspection preparation aligned with new November 2026 NMPA GMP standards. Manufacturing site documentation, quality system review, and NMPA inspector liaison management.
Registration & Post-Market
NMPA registration certificate issued. Post-market surveillance activation, adverse event reporting system, annual reporting, GMP renewal, and classification catalogue monitoring for ongoing compliance.
NMPA Registration FAQ
How long does NMPA registration take?
NMPA timelines: Class I (notification) — 5–6 months. Class II (provincial) — 15–24 months. Class III (national NMPA) — 24–32 months. Priority review under Announcement 63/2025 can significantly reduce Class III timelines for qualifying innovative devices. NexorTest’s thorough Chinese dossier preparation minimizes review queries and delays.
Do I need a Chinese agent for NMPA registration?
Yes — mandatory for all foreign manufacturers. The Chinese Registration Agent (CRA) must be a legally registered Chinese entity acting as the NMPA registration applicant. The CRA is responsible for all regulatory obligations, post-market surveillance, and adverse event reporting. NexorTest partners with established Chinese entities to provide this service.
What changed in China's 2025 NMPA regulations?
The January 2025 revised regulations clarify lifecycle quality management responsibilities, define review deadlines, and enhance post-market obligations. July 2025 Announcement 63 introduces priority review for AI devices and medical robots. November 2025 new GMP replaces 2014 standards (effective November 2026). January 2026 classification adjustments affect 31 device categories. NexorTest tracks all NMPA updates and adjusts client strategies accordingly
What does the new NMPA GMP 2026 require?
The new NMPA GMP (effective November 1, 2026) introduces more stringent QMS requirements, enhanced personnel qualification standards, strengthened supply chain and supplier management, and improved documentation traceability. All China-registered manufacturers must comply by November 2026. NexorTest provides pre-compliance gap analysis and GMP upgrade roadmaps to meet this deadline.
How does NMPA regulate SaMD and AI devices?
SaMD with high-risk functions is classified as Class III under 2025 NMPA updates. AI-driven devices qualify for priority review under Announcement 63/2025. NMPA requires algorithm validation data, clinical performance data, cybersecurity assessments, and IEC 62304 software lifecycle documentation. NexorTest provides specialized SaMD/AI NMPA registration services.
Is home country approval required for China?
Yes — NMPA requires proof of home country regulatory approval as part of the technical dossier. CE marking (EU MDR), FDA clearance/approval, or TGA Australia approval certificates are the most commonly accepted. Having CE or FDA approval significantly strengthens the NMPA submission and demonstrates device safety and efficacy in recognized reference markets.
Ready to Enter the World's Second-Largest Medical Device Market?
Get a free NMPA regulatory assessment. Our experts will classify your device under the updated 2025–2026 NMPA regulations and map the optimal registration strategy.